Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma

NCT07414979 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT07414979
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07414979 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
March 22, 2030
Enrollment
8 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leptomeningeal melanoma